Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Meghan Salcedo; Nikoletta Lendvai; Donna Mastey; Julia Schlossman; Malin Hultcrantz; Neha Korde; Sham Mailankody; Alexander Lesokhin; Hani Hassoun; Eric Smith; Urvi Shah; Victoria Diab; Kelly Werner; Heather Landau; Oscar Lahoud; Pamela Drullinsky; Gunjan Shah; David Chung; Michael Scordo; Sergio Giralt; Ola Landgren

doi:10.1016/j.clml.2019.12.013

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, Julia Schlossman, Malin Hultcrantz, Neha Korde, Sham Mailankody, Alexander Lesokhin, Hani Hassoun, Eric Smith, Urvi Shah, Victoria Diab, Kelly Werner, Heather Landau, Oscar Lahoud, Pamela Drullinsky, Gunjan Shah, David Chung, Michael Scordo, Sergio GiraltOla Landgren

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	198-200
Number of pages	3
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.clml.2019.12.013
State	Published - Mar 2020
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2019.12.013

Cite this

Salcedo, M., Lendvai, N., Mastey, D., Schlossman, J., Hultcrantz, M., Korde, N., Mailankody, S., Lesokhin, A., Hassoun, H., Smith, E., Shah, U., Diab, V., Werner, K., Landau, H., Lahoud, O., Drullinsky, P., Shah, G., Chung, D., Scordo, M., ... Landgren, O. (2020). Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 20(3), 198-200. https://doi.org/10.1016/j.clml.2019.12.013

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. / Salcedo, Meghan; Lendvai, Nikoletta; Mastey, Donna; Schlossman, Julia; Hultcrantz, Malin; Korde, Neha; Mailankody, Sham; Lesokhin, Alexander; Hassoun, Hani; Smith, Eric; Shah, Urvi; Diab, Victoria; Werner, Kelly; Landau, Heather; Lahoud, Oscar; Drullinsky, Pamela; Shah, Gunjan; Chung, David; Scordo, Michael; Giralt, Sergio; Landgren, Ola.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, No. 3, 03.2020, p. 198-200.

Research output: Contribution to journal › Letter › peer-review

Salcedo, M, Lendvai, N, Mastey, D, Schlossman, J, Hultcrantz, M, Korde, N, Mailankody, S, Lesokhin, A, Hassoun, H, Smith, E, Shah, U, Diab, V, Werner, K, Landau, H, Lahoud, O, Drullinsky, P, Shah, G, Chung, D, Scordo, M, Giralt, S & Landgren, O 2020, 'Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia, vol. 20, no. 3, pp. 198-200. https://doi.org/10.1016/j.clml.2019.12.013

Salcedo, Meghan ; Lendvai, Nikoletta ; Mastey, Donna ; Schlossman, Julia ; Hultcrantz, Malin ; Korde, Neha ; Mailankody, Sham ; Lesokhin, Alexander ; Hassoun, Hani ; Smith, Eric ; Shah, Urvi ; Diab, Victoria ; Werner, Kelly ; Landau, Heather ; Lahoud, Oscar ; Drullinsky, Pamela ; Shah, Gunjan ; Chung, David ; Scordo, Michael ; Giralt, Sergio ; Landgren, Ola. / Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. In: Clinical Lymphoma, Myeloma and Leukemia. 2020 ; Vol. 20, No. 3. pp. 198-200.

@article{667eade3f2b84ebb9d2d4d57cb89d967,

title = "Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",

author = "Meghan Salcedo and Nikoletta Lendvai and Donna Mastey and Julia Schlossman and Malin Hultcrantz and Neha Korde and Sham Mailankody and Alexander Lesokhin and Hani Hassoun and Eric Smith and Urvi Shah and Victoria Diab and Kelly Werner and Heather Landau and Oscar Lahoud and Pamela Drullinsky and Gunjan Shah and David Chung and Michael Scordo and Sergio Giralt and Ola Landgren",

note = "Funding Information: Funding support for this publication was provided by National Institute of Health-Memorial Sloan Kettering Core Grant (P30 CA0087448), Takeda Pharmaceutical Company , and Karyopharm Therapeutics . Funding Information: Dr Landgren reports grant support from the National Institutes of Health, United States Food and Drug Administraion, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm; honoraria/advisory boards from Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer; Independent Data Monitoring Committee (IDMC) from Takeda, Merck, Janssen, and Theradex. Dr Urvi Shah reports honorarium from the Physicians{\textquoteright} Education Resource. The remaining authors have stated that they have no conflicts of interest. ",

year = "2020",

month = mar,

doi = "10.1016/j.clml.2019.12.013",

language = "English (US)",

volume = "20",

pages = "198--200",

journal = "Clinical Lymphoma",

issn = "2152-2669",

publisher = "Cancer Media Group",

number = "3",

}

TY - JOUR

T1 - Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

AU - Salcedo, Meghan

AU - Lendvai, Nikoletta

AU - Mastey, Donna

AU - Schlossman, Julia

AU - Hultcrantz, Malin

AU - Korde, Neha

AU - Mailankody, Sham

AU - Lesokhin, Alexander

AU - Hassoun, Hani

AU - Smith, Eric

AU - Shah, Urvi

AU - Diab, Victoria

AU - Werner, Kelly

AU - Landau, Heather

AU - Lahoud, Oscar

AU - Drullinsky, Pamela

AU - Shah, Gunjan

AU - Chung, David

AU - Scordo, Michael

AU - Giralt, Sergio

AU - Landgren, Ola

N1 - Funding Information: Funding support for this publication was provided by National Institute of Health-Memorial Sloan Kettering Core Grant (P30 CA0087448), Takeda Pharmaceutical Company , and Karyopharm Therapeutics . Funding Information: Dr Landgren reports grant support from the National Institutes of Health, United States Food and Drug Administraion, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm; honoraria/advisory boards from Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer; Independent Data Monitoring Committee (IDMC) from Takeda, Merck, Janssen, and Theradex. Dr Urvi Shah reports honorarium from the Physicians’ Education Resource. The remaining authors have stated that they have no conflicts of interest.

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85081071233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081071233&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.12.013

DO - 10.1016/j.clml.2019.12.013

M3 - Letter

C2 - 32001193

AN - SCOPUS:85081071233

VL - 20

SP - 198

EP - 200

JO - Clinical Lymphoma

JF - Clinical Lymphoma

SN - 2152-2669

IS - 3

ER -

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this